CL2011002664A1 - Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. - Google Patents

Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Info

Publication number
CL2011002664A1
CL2011002664A1 CL2011002664A CL2011002664A CL2011002664A1 CL 2011002664 A1 CL2011002664 A1 CL 2011002664A1 CL 2011002664 A CL2011002664 A CL 2011002664A CL 2011002664 A CL2011002664 A CL 2011002664A CL 2011002664 A1 CL2011002664 A1 CL 2011002664A1
Authority
CL
Chile
Prior art keywords
vector
nucleic acid
procedure
cxcr4
study
Prior art date
Application number
CL2011002664A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002664(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2011002664A1 publication Critical patent/CL2011002664A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2011002664A 2009-04-29 2011-10-26 Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4. CL2011002664A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17368009P 2009-04-29 2009-04-29
EP09159076A EP2246364A1 (en) 2009-04-29 2009-04-29 Anti CXCR4 antibodies for the treatment of HIV

Publications (1)

Publication Number Publication Date
CL2011002664A1 true CL2011002664A1 (es) 2012-12-14

Family

ID=41060014

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002664A CL2011002664A1 (es) 2009-04-29 2011-10-26 Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.

Country Status (26)

Country Link
US (3) US9090686B2 (es)
EP (2) EP2246364A1 (es)
JP (1) JP5800802B2 (es)
KR (1) KR20120039525A (es)
CN (1) CN102459343B (es)
AU (1) AU2010243526B2 (es)
BR (2) BRPI1011540A2 (es)
CA (1) CA2759989A1 (es)
CL (1) CL2011002664A1 (es)
CO (1) CO6390114A2 (es)
ES (1) ES2534313T3 (es)
GE (1) GEP20146181B (es)
HK (1) HK1165813A1 (es)
HU (1) HUE025083T2 (es)
IL (1) IL215919A0 (es)
MA (1) MA33285B1 (es)
MX (1) MX2011011285A (es)
MY (1) MY155400A (es)
NZ (1) NZ596712A (es)
PL (1) PL2424897T3 (es)
RU (1) RU2573902C2 (es)
SG (1) SG175353A1 (es)
TN (1) TN2011000534A1 (es)
UA (1) UA107929C2 (es)
WO (1) WO2010125162A1 (es)
ZA (1) ZA201108330B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9587012B2 (en) 2013-12-02 2017-03-07 Aaron Diamond Aids Research Center Bispecific HIV-1 neutralizing antibodies
NZ743713A (en) 2015-12-15 2020-01-31 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CA3167936A1 (en) * 2020-01-16 2021-07-22 Cohava Gelber Humanized antibodies specific for myeloma and ovarian cancer cells
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5871732A (en) * 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69334287D1 (de) * 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
KR20090052358A (ko) * 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
JP5374360B2 (ja) * 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗ｃｘｃｒ４抗体
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2011059684A1 (en) * 2009-10-29 2011-05-19 Centocor Ortho Biotech Inc. Antibody glycosylation variants
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
MX2011011285A (es) 2012-01-20
PL2424897T3 (pl) 2015-07-31
KR20120039525A (ko) 2012-04-25
EP2246364A1 (en) 2010-11-03
UA107929C2 (en) 2015-03-10
RU2011148077A (ru) 2013-06-10
ZA201108330B (en) 2012-09-26
US20160031995A1 (en) 2016-02-04
BRPI1011540A2 (pt) 2019-04-30
JP2012525129A (ja) 2012-10-22
MY155400A (en) 2015-10-15
IL215919A0 (en) 2011-12-29
CO6390114A2 (es) 2012-02-29
ES2534313T3 (es) 2015-04-21
CA2759989A1 (en) 2010-11-04
AU2010243526B2 (en) 2015-02-12
WO2010125162A1 (en) 2010-11-04
HK1165813A1 (en) 2012-10-12
JP5800802B2 (ja) 2015-10-28
AU2010243526A1 (en) 2011-12-22
US20130174288A1 (en) 2013-07-04
SG175353A1 (en) 2011-11-28
US20110088104A1 (en) 2011-04-14
MA33285B1 (fr) 2012-05-02
CN102459343B (zh) 2015-09-16
TN2011000534A1 (en) 2013-05-24
NZ596712A (en) 2013-10-25
GEP20146181B (en) 2014-10-27
RU2573902C2 (ru) 2016-01-27
BR112013009984A2 (pt) 2017-07-18
EP2424897B1 (en) 2015-01-07
HUE025083T2 (en) 2016-02-29
EP2424897A1 (en) 2012-03-07
US9090686B2 (en) 2015-07-28
CN102459343A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CL2011002664A1 (es) Anticuerpo anti-cxcr4 aislado o un fragmento funcional del mismo; acido nucleico que lo codifica; vector que comprende dicho ácido nucleico; celula huesped que comprende dicho vector; procedimiento de produccion; composicion que lo comprende; su uso para prevenir o tratar la infeccion por vih; y procedimiento para el estudio y/o identificacion de moleculas antivirales antagonistas de cxcr4.
CL2013002044A1 (es) Anticuerpo que une il-17a humano e il-17f humano; secuencia de adn que lo codifica; vector; celula huesped; proceso de produccion; composicion farmaceutica que lo comprende; y su uso para el tratamiento profilaxis de un trastorno patologico mediado por il-17a y/o il-17f.
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
CL2015000665A1 (es) Compuesto análogo de glucagón útil para prevenir ganancia de peso o promover pérdida de peso; ácido nucleico que lo codifica; vector; célula huésped; kit; y procedimiento de producción.
CL2014000291A1 (es) Vacuna que comprende al menos 30 aminoacidos de un polipeptido de p62/sqstm1 o un acido nucleico que lo codifica; y su uso para el tratamiento y profilaxis del cancer.
CL2015000420A1 (es) Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3.
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2007001840A1 (es) Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
CL2013001121A1 (es) Acido ribonucleico interferente; polinucleotido que lo codifica; construccion de adn que lo codifica; celula huesped; composicion que lo comprende; y su uso para la prevencion y/o control de la infestacion por plaga.
CL2013001403A1 (es) Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
BR112012022210A2 (pt) anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112015010817A2 (pt) anticorpos anti-hemaglutinina, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
CL2013000868A1 (es) Anticuerpo aislado que se une al complejo i del citomegalovirus humano (hcmv) o al gh de hcmv; acido nucleico que lo codifica; celula huesped; metodo de produccion; composicion que lo comprende; y su uso para tratar, inhibir o prevenir la infeccion por hcmv.
CL2013001290A1 (es) Anticuerpo aislado, o su fragmento, que se une a beta secretasa (bace1); acido nucleico que codifica el anticuerpo; celula huesped que comprende el acido nucleico; metodo para producir un anticuerpo; inmunoconjugado que comprende el anticuerpo; formulacion farmaceutica; uso del anticuerpo para tratar enfermedad o trastorno neurológico.
CL2015000114A1 (es) Anticuerpo anti-fractalkina (anti-fkn): composición farmacéutica que comprende dicho anticuerpo anti-fkn; ácido nucleico; vector; célula huésped; uso del anticuerpo anti-fkn para tratar colitis ulcerosa, enfermedad de crohn, o artritis reumática
CL2012002415A1 (es) Anticuerpo monoclonal aislado que se une al inhibidor de la via del factor tisular humano (tfpi); composicion farmacéutica que comprende dicho anticuerpo; procedimientos para tratar deficiencias o defectos genéticos o adquiridos en la coagulación; molecula de acido nucleico que codifica el anticuerpo; vector y célula huesped.
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.
WO2013020074A3 (en) A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
CL2008000820A1 (es) Anticuerpo aislado o fragmentos funcionales con capacidad para neutralizar cepas hiv; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir un anticuerpo; uso del anticuerpo para el tratamie
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.